PolyNovo Limited (ASX:PNV): How Are FY26 Sales, Cash Flow and Manufacturing Plans Developing?

Aditi Sarkar

29 October 2026 03:28 PM AEDT

PolyNovo Limited (ASX:PNV): How Are FY26 Sales, Cash Flow and Manufacturing Plans Developing?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo (ASX:PNV) reported FY26 total revenue of AUD 150.0 million, up 16.1% YoY.
Commercial product sales increased 16.7% YoY to AUD 138.4 million.
FY26 EBITDA was AUD 12.1 million, while operating cash flow reached AUD 23.1 million.
The company plans manufacturing scale-up and further US regulatory and outpatient initiatives in FY27.

PolyNovo Limited develops and commercialises medical devices for the treatment of burns and complex wounds, with its NovoSorb platform sold across multiple international markets. The company entered FY27 after reporting higher FY26 product sales, positive operating cash flow and progress on its Port Melbourne manufacturing expansion. On 29 October 2026, PolyNovo (ASX:PNV) remained an ASX-listed healthcare business, although a reliable intraday quotation for that session could not be independently established. Its latest reported results place product adoption, production capacity and regulatory activities at the centre of the next reporting period.

Company Business

PolyNovo (ASX:PNV) focuses on its NovoSorb biodegradable polymer technology. NovoSorb Biodegradable Temporising Matrix (BTM) is used in reconstructive treatment of wounds, while NovoSorb MTX broadens the company’s commercial product range. The company distributes products through a combination of direct sales operations and partners, including in the United States and markets outside the US. The US accounts for the largest portion of its commercial sales, making hospital relationships, procedural adoption and reimbursement important operating considerations.

The company also works on clinical evidence and regulatory submissions intended to support additional indications and settings of care. Its expanded manufacturing operations in Port Melbourne are designed to support higher product volumes. This creates a connection between clinical adoption, supply reliability, manufacturing expenditure and the economics of future commercial expansion.

Recent Development

In its August 2026 full-year release, PolyNovo (ASX:PNV) reported commercial product sales of AUD 138.4 million for FY26, compared with AUD 118.6 million in FY25. Sales increased 21.3% on a constant-currency basis. US product sales reached AUD 102.1 million, up 15.6% on a reported basis, while rest-of-world commercial sales reached AUD 36.3 million, up 20.0%. These figures show growth across both the principal US market and the company’s other commercial territories.

NovoSorb BTM generated AUD 125.8 million of global sales and NovoSorb MTX generated AUD 12.6 million, according to the FY26 investor presentation. Management also identified progress in clinical evidence, the US premarket approval programme for BTM in full-thickness burns and an outpatient strategy. Construction of a new manufacturing facility was completed, with validation activities continuing ahead of a planned transition in FY27.

PolyNovo scheduled its annual general meeting for 30 October 2026. The meeting provides a forum for discussion of the FY26 financial statements, governance resolutions and management’s priorities, rather than constituting a new set of reported financial results.

Financial Performance and Sector Context

PolyNovo (ASX:PNV) recorded FY26 total revenue of AUD 150.0 million, an increase from AUD 129.2 million in FY25. EBITDA increased 8.1% from AUD 11.2 million to AUD 12.1 million. Net profit after tax, however, fell from AUD 13.2 million to AUD 7.3 million. The prior year included an income tax benefit, whereas FY26 recorded a tax expense, affecting the year-on-year profit comparison.

Operating cash flow increased to AUD 23.1 million from AUD 3.1 million, and free cash flow was AUD 9.4 million. Cash and cash equivalents stood at AUD 35.4 million at the end of June 2026, compared with AUD 33.5 million a year earlier. Gross margin was 89.0%, down from 95.6% in FY25, providing a counterpoint to product-sales growth and improved cash conversion.

In medical technology, expansion requires investment in clinical evidence, regulatory processes, practitioner training and manufacturing controls. Currency movements also matter because PolyNovo earns revenue in several markets while reporting in Australian dollars. Commercial demand, adoption by healthcare providers and the timing of approvals can therefore affect reported results independently of headline product-sales growth.

Risks to Consider

The business faces regulatory timing and clinical-evidence risks as it seeks broader use of NovoSorb products. Scaling the expanded factory requires validation, quality controls and consistent yields; delays could affect supply or costs. Gross-margin variation, foreign-exchange changes, competing wound-management products and hospital purchasing decisions may influence earnings. The difference between positive EBITDA and lower statutory NPAT also underlines the need to assess the full income statement, not a single performance measure.

What to Watch Next

For PolyNovo (ASX:PNV), FY27 monitoring points include the validation and ramp-up of its Port Melbourne manufacturing capacity, progress on the US BTM regulatory submission and the planned outpatient-market strategy. Investors can also examine sales by geography and by NovoSorb product, operating cash flow and whether manufacturing economics stabilise as volumes increase. Updates from the 30 October annual general meeting and subsequent company disclosures may provide additional detail on the implementation of these plans.

Key Insights

PolyNovo (ASX:PNV) closed FY26 with higher reported revenue, a larger MTX sales contribution and improved operating cash flow, alongside lower net profit and a narrower gross margin. Its FY27 programme involves manufacturing validation, broader clinical applications and commercial expansion. Subsequent financial releases will help determine how these operational initiatives translate into sales mix, cash generation and reported profitability.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.